The Clinical Observation Of Montelukast Association With Budesonide On Patients With Bronchial Asthma

Background:Bronchial asthma is the world's most common diseases, which can occur in different sex of all ages.Asthma has reached the world's nearly 150 million years. There were 180,000 people die of asthma. In our country the incidence of asthma is about 1%. Asthma is an eosinophil and mast cell reaction consisting mainly of allergic airway inflammation and airway hyperresponsiveness characteristic of the disease. Global initiative forbronchial asthma stressed that asthma was a chronic inflammatory airway diseases and ecommended long-term maintenance of corticosteroid therapy as the basis of anti-inflammatory treatment. Inhalation due to high concentrations of the drug can act directly on airway partially, the rapid onset and as the preferred method of treatment. Leukotriene is a strong inflammatory mediators, which play an important role in the pathogenesis of asthma. And glucocorticoids can not inhibit the synthesis of leukotrienes and release. Encore to (La扎鲁斯特20xl tablets) and Ning Heshun (montelukast to 10nl film) is a commonly used leukotriene receptor modulator, which can reduce asthma symptoms and improve lung function and reduce the deterioration of asthma; However, its role as inhaled glucocorticoid type and not a substitute for corticosteroids. As a combination therapy of a drug, it can be reduced in patients with a severe asthma inhaled glucocorticoid dose to increase the efficacy of inhaled corticosteroid.Objective: To observe the joint Montelukast Budesonide treatment of adult bronchial asthma in clinical efficacy.Methods: moderate and severe bronchial asthma in 42 cases of patients with acute exacerbation were randomly divided into two groups.Both the control group and the experimental group are 21 cases. The control group used antibiotics, Doxofylline, 0.9% saline+3 milliliters Snyder Budesonide 2 mg twice a day, 0.9% saline+3 milliliters terbutaline sulfate 0.25 twice a day inhalation treatment. The experimental group used antibiotics, Doxofylline, 0.9% saline+3 milliliters Snyder Budesonide 2 mg twice a day, 0.9% saline three milliliters+0.25 terbutaline sulfate on the treatment of two inhalation, Montelukast 10 mg orally before going to bed on time. Treatment of 10 days. Records of treatment during hospitalization in patients with asthma symptoms during the day and night episodes; Clinical symptoms were observed to alleviate the time; The two groups before treatment, 10 days after treatment, were given a pulmonary function test. At the same time after discharge from hospital records of two groups of re-hospitalization rate. Results: 1,Montelukast Budesonide inhalation can be effective in improving asthma in patients with severe lung function indicators, Alleviating the symptoms of asthma. The improvement of the experimental group becomes more apparent than the control group. 2,the experimental group-like episodes during the day and at night episodes are less than the control group.